GlassScriptPhysician profile
Warren Roquet
NPI 1275604878
$7,950.64
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,999 · 2020: $1,812 · 2021: $2,223 · 2022: $1,518 · 2023: $369 · 2024: $29.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $398.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,665.12 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $691.45 | 2019-2020 | |
| Pfizer INC. | $599.87 | 2019-2023 | |
| Abbvie INC. | $589.57 | 2019-2023 | Vraylar |
| Amarin Pharma, INC. | $505.42 | 2019-2022 | |
| Lilly USA, LLC | $396.78 | 2020-2023 | Jardiance, Emgality |
| Astellas Pharma US INC | $388.25 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $345.92 | 2019-2023 | Spravato |
| Sanofi-Aventis U.S. LLC | $300.05 | 2019-2023 | |
| Amgen INC. | $298.94 | 2019-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.84 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $228.59 | 2022 | |
| Boston Scientific Corporation | $217.19 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $183.50 | 2019-2023 | Belsomra, Steglatro |
| Kowa Pharmaceuticals America, INC. | $150.90 | 2020-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Roquet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.